Intellia Therapeutics, Inc. (NASDAQ:NTLA) Stock Holdings Trimmed by Quest Partners LLC

Quest Partners LLC lessened its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 28.5% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 7,014 shares of the company’s stock after selling 2,793 shares during the period. Quest Partners LLC’s holdings in Intellia Therapeutics were worth $157,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Blue Trust Inc. raised its holdings in shares of Intellia Therapeutics by 1,664.3% during the second quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock worth $33,000 after purchasing an additional 1,398 shares during the period. First Horizon Advisors Inc. boosted its holdings in shares of Intellia Therapeutics by 22.1% during the second quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock valued at $58,000 after acquiring an additional 472 shares during the period. GAMMA Investing LLC grew its position in shares of Intellia Therapeutics by 1,322.0% during the second quarter. GAMMA Investing LLC now owns 2,645 shares of the company’s stock worth $59,000 after acquiring an additional 2,459 shares during the last quarter. EntryPoint Capital LLC increased its holdings in shares of Intellia Therapeutics by 61.1% in the 1st quarter. EntryPoint Capital LLC now owns 4,122 shares of the company’s stock worth $113,000 after acquiring an additional 1,563 shares during the period. Finally, AdvisorNet Financial Inc lifted its position in Intellia Therapeutics by 63.5% in the 2nd quarter. AdvisorNet Financial Inc now owns 5,100 shares of the company’s stock valued at $114,000 after purchasing an additional 1,980 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. StockNews.com upgraded Intellia Therapeutics to a “sell” rating in a research report on Thursday, June 27th. Cantor Fitzgerald reiterated an “overweight” rating and set a $65.00 price target on shares of Intellia Therapeutics in a research report on Monday, June 24th. Stifel Nicolaus decreased their price target on Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating for the company in a research note on Wednesday, September 11th. Royal Bank of Canada cut their price objective on shares of Intellia Therapeutics from $60.00 to $54.00 and set an “outperform” rating on the stock in a research note on Friday, August 9th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, August 12th. One research analyst has rated the stock with a sell rating, four have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $61.77.

Intellia Therapeutics Stock Up 6.8 %

NTLA stock opened at $22.07 on Monday. The company has a 50 day moving average of $23.41 and a two-hundred day moving average of $24.40. Intellia Therapeutics, Inc. has a 12-month low of $19.21 and a 12-month high of $36.25. The company has a market cap of $2.24 billion, a price-to-earnings ratio of -4.12 and a beta of 1.77.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, August 8th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.29). The company had revenue of $7.00 million during the quarter, compared to analysts’ expectations of $19.68 million. During the same period last year, the firm posted ($1.40) earnings per share. The company’s revenue was down 48.5% on a year-over-year basis. On average, research analysts anticipate that Intellia Therapeutics, Inc. will post -5.19 EPS for the current year.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.